|
EQS-Ad-hoc: Dermapharm Holding SE / Key word(s): Dividend Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse Dermapharm Holding SE: 2022 dividend Grünwald, 22 March 2023 – At its meeting today, the Board of Management of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) resolved to propose to the Company's Annual General Meeting, which is expected to be held on 14 June 2023, the distribution of a dividend for the 2022 financial year amounting to EUR 1.05 per no-par value share carrying dividend rights (previous year: EUR 2.17 per share). The proposed dividend corresponds to a total distribution of EUR 56.5 million (previous year: EUR 116.8 million). This represents a distribution ratio of 42% of the expected consolidated profit or loss of EUR 134.2 million. The distribution ratio in financial year 2021 was 56%. The Board of Management's goal in reducing the distribution ratio as compared to the previous financial year is to ensure that financial liabilities can be repaid quickly. The proposal for the appropriation of net retained earnings is subject to the approval of the Supervisory Board, which will resolve on the matter at its meeting to discuss the annual financial statements on 27 March 2023. Note: Consolidated profit or loss is an alternative performance measure that is not defined in international accounting standards. Dermapharm Holding SE defines consolidated profit or loss as follows: consolidated net profit or loss for the year/period (after financing interest and taxes) excluding non-controlling interests. It represents the amount remaining after deducting all operating expenses, interest and taxes from the Company's total revenue. It is a key indicator of how successfully the Company has performed in a given period. >End of ad hoc disclosure< Contact Investor Relations & Corporate Communications
22-March-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Dermapharm Holding SE |
| Lil-Dagover-Ring 7 | |
| 82031 Grünwald | |
| Germany | |
| Phone: | +49 (0)89 64 86-0 |
| E-mail: | ir@dermapharm.com |
| Internet: | ir.dermapharm.de |
| ISIN: | DE000A2GS5D8 |
| WKN: | A2GS5D |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1589203 |
| End of Announcement | EQS News Service |
|
|
1589203 22-March-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
